Estriol

Overview

Estriol is a short-acting estrogen used in veterinary medicine for the management of urinary incontinence in spayed female dogs with urethral sphincter mechanism incompetence (USMI). It is specifically approved for use in ovariohysterectomized bitches.

Unlike other estrogens, estriol has a relatively short duration of receptor binding, which contributes to a lower risk of long-term adverse effects such as myelotoxicity while still maintaining therapeutic efficacy. Treatment is typically individualized, with dose adjustments aimed at achieving the lowest effective dose.

Mechanism of Action (MOA): Estriol binds to estrogen receptors in the lower urinary tract, enhancing urethral sphincter tone. This effect is mediated through increased sensitivity of urethral smooth muscle to norepinephrine, resulting in improved sphincter contractility and urinary continence.

Indications

Estriol is used in dogs for the management of urinary incontinence associated with reduced urethral sphincter tone. Its use is specific to estrogen-responsive conditions in appropriately selected patients.

• Urethral sphincter mechanism incompetence (USMI): Primary indication in spayed female dogs, where decreased estrogen levels lead to reduced urethral sphincter tone and urinary leakage.
• Estrogen-responsive urinary incontinence: Used to improve continence by enhancing urethral closure function in ovariohysterectomized bitches.

Dosage (Reference)

Dog

Estriol is administered orally in dogs for the management of urinary incontinence. Dosing is not based on body weight and should be individualized, with gradual adjustment to the lowest effective dose.

Cat

Estriol is not recommended for use in cats.

Warnings & Precautions

Estriol is an estrogenic drug that requires appropriate patient selection and cautious use due to hormonal effects and potential systemic risks.

• Restricted use population: Contraindicated in male dogs, intact female dogs, dogs less than 1 year of age, and pregnant or lactating animals.
• Concurrent estrogen therapy: Do not use with other estrogen-containing medications due to risk of additive effects.
• Polyuria/polydipsia (PU/PD): Avoid use in dogs exhibiting PU/PD as underlying conditions may be worsened.
• Liver disease: Use with caution in patients with hepatic disease due to potential alterations in drug metabolism.
• Concurrent glucocorticoids: Safety has not been established; use cautiously when combined.
• Hazardous drug handling: Estrogens are classified as hazardous; appropriate personal protective equipment (PPE) should be used during handling.
• Drug confusion risk: Do not confuse estriol with estradiol, as they differ significantly in pharmacologic profile and safety.

Drug Interactions

Clinically relevant drug interactions with estriol are primarily related to changes in estrogen concentration or additive hormonal effects.

• Anticoagulants (e.g., heparins, warfarin, rivaroxaban): May reduce anticoagulant effectiveness.
• Ascorbic acid: May increase estrogen concentrations.
• Azole antifungals (e.g., ketoconazole, itraconazole, fluconazole): May increase estrogen concentrations.
• Cimetidine: May increase estrogen concentrations.
• Cyclosporine: May increase serum cyclosporine levels.
• Hypoglycemic agents (e.g., insulin, metformin, glipizide): May increase blood glucose levels.
• Other estrogens (e.g., diethylstilbestrol): Additive effects; concurrent use should be avoided.
• Levothyroxine: May reduce its therapeutic effect; dose adjustment and monitoring may be required.
• Macrolide antibiotics (e.g., erythromycin, clarithromycin): May increase estrogen concentrations.
• Mitotane: May decrease estrogen concentrations.
• Phenobarbital: May decrease estrogen concentrations.
• Rifampin: May decrease estrogen concentrations.
• Theophylline / aminophylline: May increase theophylline concentrations.
• Thyroid hormones: May alter thyroid hormone levels.
• Ursodiol: May reduce ursodiol effectiveness.

Side Effects & Overdose

Side Effects

Adverse effects of estriol are generally mild and dose-dependent, with most related to gastrointestinal or estrogenic effects.

• Gastrointestinal effects: Hyporexia and vomiting are the most commonly reported.
• Estrogenic effects: Swollen vulva (most common), vulvovaginitis, mammary hyperplasia, behavioral changes, and increased attractiveness to male dogs.
• Less common effects: Polydipsia, lethargy, hyperactivity, aggression, and localized alopecia.
• Rare effects: Blood dyscrasias, vaginal bleeding, and increased incidence of seizures.
• Reversibility: Most adverse effects are reversible with dose reduction.

Overdose

Acute overdose is unlikely to result in life-threatening toxicity, but exaggerated estrogenic effects may occur, especially with prolonged or high-dose exposure.

• Acute overdose: May cause vomiting or other gastrointestinal signs.
• Estrogenic effects: May occur in both males (feminization) and females.
• Chronic overdose: May lead to vulvar swelling, discharge, mammary hyperplasia, and increased white blood cell and platelet counts.
• Management: Supportive care and dose reduction or discontinuation as needed.

Key Notes

Practical clinical points that help optimize the safe and effective use of estriol in dogs:

• Non–weight-based dosing: Unlike most veterinary drugs, dosing is standardized per dog rather than calculated by body weight.
• Stepwise titration approach: Dose adjustments should be made gradually based on clinical response rather than rapid changes.
• Rapid absorption: Oral estriol is almost completely absorbed, with peak plasma levels occurring relatively quickly (≈1 hour).
• Enterohepatic recirculation: Multiple plasma concentration peaks may occur due to recycling through the liver and intestines.
• Urinary excretion: Eliminated primarily via urine, including conjugated metabolites.
• Selective clinical use: Specifically designed for use in spayed female dogs rather than broad estrogen therapy.
• Lower tumorigenic potential: Compared to some other estrogen analogs, estriol may have a reduced risk of tumor development.
• Protein binding characteristics: Weak plasma protein binding contributes to its shorter duration of action.